Modulators of the urokinase-type plasminogen activation system for cancer

Bibliography

• Schmitt M, Jaenicke F, Moniwa N, Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 1992;373:611-22
   PubMed Web of Science ®Google Scholar
• Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988;2:73-84
   Google Scholar
• Dano K, Andreasen PA, Gronahl-Hansen J, Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266
   PubMed Web of Science ®Google Scholar
• Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36
   PubMed Web of Science ®Google Scholar
• Andreasen PA, Egelund R, Petersen HH. The plasminogen activator system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40
   PubMed Web of Science ®Google Scholar
• Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43
   PubMed Web of Science ®Google Scholar
• Hildenbrand R, Gandhari M, Stroebel P, The urokinase-system-role of cell proliferation and apoptosis. Histol Histopathol 2008;23:227-36
   PubMed Web of Science ®Google Scholar
• Killeen S, Hennessey A, El Hassan Y, Waldron B. The urokinase activator system in cancer: a putative therapeutic target? Drug News Perspect 2008;21:107-16
   PubMed Web of Science ®Google Scholar
• Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009;148:43-66
   PubMedGoogle Scholar
• Wei Y, Lukashev M, Simon DI, Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5
   PubMed Web of Science ®Google Scholar
• Wei Y, Waltz DA, Rao N, Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8
   PubMed Web of Science ®Google Scholar
• Deng G, Curriden SA, Wang S, Is plasminogen activator inhibitor -1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-71
   PubMed Web of Science ®Google Scholar
• Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57
   PubMed Web of Science ®Google Scholar
• Wei Y, Yang X, Liu Q, A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999;144:1285-94
   PubMed Web of Science ®Google Scholar
• Nguyen DHD, Catling AD, Webb DJ, Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 1999;146:149-64
   PubMed Web of Science ®Google Scholar
• Hildenbrand R, Arens N. Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br J Cancer 2004;91:564-71
   PubMed Web of Science ®Google Scholar
• Danø K, Behrendt N, Høyer-Hansen G, Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Porta C, Inflammation and cancer: breast cancer as a prototype. Breast 2007;16:27-33
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83
   PubMed Web of Science ®Google Scholar
• Hildenbrand R, Wolf G, Böhme B, Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999;66:40-9
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sawaya R, Mohanam S Rao VH, Expression and localization of urokinase plasminogen activator receptor in human gliomas. Cancer Res 1994;54:5016-20
   PubMed Web of Science ®Google Scholar
• Dublin E, Hanby A, Patel NK, Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 2000;157:1219-27
   PubMed Web of Science ®Google Scholar
• Giannopoulou I, Mylona E, Kapranou A, The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett 2007;246:262-7
   PubMed Web of Science ®Google Scholar
• Hildenbrand R, Niedergethmann M, Marx A, Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009;174:2246-53
   PubMed Web of Science ®Google Scholar
• Park IK, Kim BJ, Goh YJ, Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity. Int J Cancer 1997;71:867-73
   PubMed Web of Science ®Google Scholar
• Suzuki S, Hayashi Y, Wang Y, Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut 1998;43:798-805
   PubMed Web of Science ®Google Scholar
• Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-9
   PubMed Web of Science ®Google Scholar
• Fischer K, Lutz V, Wilhelm O, Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett 1998;438:101-5
   PubMed Web of Science ®Google Scholar
• Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastasis in vivo. Cancer Res 2002;62:2390-7
   PubMed Web of Science ®Google Scholar
• Bauer TW, Liu W, Fan F, Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005;65:7775-81
   PubMed Web of Science ®Google Scholar
• Hu XW, Duan HF, Gao LH, Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol Ther 2008;7:651-9
   PubMed Web of Science ®Google Scholar
• Sidenius N, Andolfo A, Fesce R, Blasi F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem 2002;277:27982-90
   PubMed Web of Science ®Google Scholar
• Dunn SE, Torres JV, Nihei N, Barrett JC. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol Carcinog 2000;27:10-7
   PubMed Web of Science ®Google Scholar
• Zou Z, Anisowicz A, Hendrix MJ, Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-9
   PubMed Web of Science ®Google Scholar
• Cher ML, Biliran HR Jr, Bhagat S, Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 2003;100:7847-52
   PubMed Web of Science ®Google Scholar
• Yin S, Lockett J, Meng Y, Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 2006;66:4173-81
   PubMed Web of Science ®Google Scholar
• Zhu F, Jia S, Xing G, cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. DNA Cell Biol 2001;20:297-305
   PubMed Web of Science ®Google Scholar
• Li H, Lu H, Griscelli F, Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther 1998;5:1105-13
   PubMed Web of Science ®Google Scholar
• Li H, Griscelli F, Lindenmeyer F, Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum Gene Ther 1999;10:3045-53
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Gotoh J, Fujie M, Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994;57:727-33
   PubMed Web of Science ®Google Scholar
• Bürgle M, Koppitz M, Riemer C, Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997;378:231-7
   PubMed Web of Science ®Google Scholar
• Magdolen V, Bürgle M, de Prada NA, Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001;382:1197-205
   PubMed Web of Science ®Google Scholar
• Schmiedeberg N, Schmitt M, Rölz C, Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem 2002;45:4984-94
   PubMed Web of Science ®Google Scholar
• Sato S, Kopitz C, Schmalix WA, High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett 2002;528:212-6
   PubMed Web of Science ®Google Scholar
• Sperl S, Mueller MM, Wilhelm OG, The uPA/uPA receptor system as a target for tumor therapy. Drug News Perspect 2001;14:401-11
   PubMed Web of Science ®Google Scholar
• Lutz V, Reuning U, Krüger A, High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001;382:789-98
   PubMed Web of Science ®Google Scholar
• Krüger A, Soeltl R, Lutz V, Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000;7:292-9
   PubMed Web of Science ®Google Scholar
• Guo Y, Higaz AA, Arakelian A, A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 2000;14:1400-10
   PubMed Web of Science ®Google Scholar
• Datta A, Kitson RP, Xue Y, Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases. In Vivo 2002;16:451-7
   PubMed Web of Science ®Google Scholar
• Berkenblit A, Matulonis UA, Kroener JF, A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 2005;99:50-7
   PubMed Web of Science ®Google Scholar
• La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990;2:106-15
   PubMed Web of Science ®Google Scholar
• Ellis V, Danø K. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J 1993;296:505-10
   PubMed Web of Science ®Google Scholar
• Dreicer R, Smith DC, Williams RD, See WA. Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 1999;17:183-6
   PubMed Web of Science ®Google Scholar
• Small EJ, Meyer M, Marshall ME, Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440-50
   PubMed Web of Science ®Google Scholar
• Callahan JA, Beck I, Bauer TW, In vitro and in vivo characterization of a monoclonal antibody, ATN-658, targeting the uPA system. 2005 AACR-Meeting; Proc Amer Assoc Cancer Res 2005;46: abstract #6179. Available from: www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/1454-b
   Google Scholar
• Van Buren G II, Gray MJ, Dallas NA, Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009;115:3360-8
   PubMed Web of Science ®Google Scholar
• Kirchheimer JC, Wojta J, Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 1989;86:5424-8
   PubMed Web of Science ®Google Scholar
• Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009;9:32-71
   PubMed Web of Science ®Google Scholar
• Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987;214:187-91
   PubMed Web of Science ®Google Scholar
• Towle MJ, Lee A, Maduakor EC, Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993;53:2553-9
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Harakidas P, Davidson DJ, Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995;63:840-5
   PubMed Web of Science ®Google Scholar
• Xing RH, Mazar A, Henkin J,Rabani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997;57:3585-93
   PubMed Web of Science ®Google Scholar
• Frederickson M, Callaghan O, Chessari G, Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem 2008;51:183-6
   PubMed Web of Science ®Google Scholar
• Zhu M, Gokhale VM, Szabo L, Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther 2007;6:1348-56
   PubMed Web of Science ®Google Scholar
• Fish P, Baarber CG, Brown DG, Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem 2007;50:2341-51
   PubMed Web of Science ®Google Scholar
• Setyono-Han B, Stürzebecher J, Schmalix WA, Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005;93:779-86
   PubMed Web of Science ®Google Scholar
• Wosikowski K, Foekens J, Setyono-Han B, Antimetastatic efficacy of WX-UK1 in a resected, spontaneously metastasizing rat mammary tumor model. Proc Am Assoc Cancer Res (AACR) 2002;43: abstract 788
   Google Scholar
• Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, A novel of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2003;2:19-28
   PubMed Web of Science ®Google Scholar
• Sieńczyk M, Oleksyszyn J. Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity. Bioorg Med Chem Lett 2006;16:2886-90
   PubMed Web of Science ®Google Scholar
• Sieńczyk M, Oleksyszyn J. Irreversible inhibition of serine proteases - design and in vivo activity of diaryl alpha-aminophosphonate derivatives. Curr Med Chem 2009;16:1673-87
   PubMed Web of Science ®Google Scholar
• Lee KH, Choi EY, Hyun MS, Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis 2007;25:89-96
   PubMed Web of Science ®Google Scholar
• Webb CP, Hose CD, Koochekpour S, The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-9
   PubMed Web of Science ®Google Scholar
• Henic E, Sixt M, Hansson S, EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol Oncol 2006;101:28-39
   PubMed Web of Science ®Google Scholar
• Festuccia C, Angelucci A, Gravina GL, Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005;93:964-75
   PubMed Web of Science ®Google Scholar
• Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007;25:33-9
   PubMed Web of Science ®Google Scholar
• Mohan PM, Chintala SK, Mohanam S, Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res 1999;59:3369-73
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang X, Wu S, Inhibition of colon cancer metastasis by a 3′- end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 2001;92:257-62
   PubMed Web of Science ®Google Scholar
• Margheri F, D'Alessio S, Serratí S, Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 2005;12:702-14
   PubMed Web of Science ®Google Scholar
• Nozaki S, Endo Y, Nakahara H, Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol 2005;41:971-97
   PubMed Web of Science ®Google Scholar
• Gondi CS, Lakka SS, Dinh DH, Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007;13:4051-60
   PubMed Web of Science ®Google Scholar
• Pulukuri SM, Gondi CS, Lakka SS, RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005;280:36529-40
   PubMed Web of Science ®Google Scholar
• Guo Y, Pakneshan P, Gladu J, Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 2000;277:41571-9
   Web of Science ®Google Scholar
• Chekhun VF, Kulik GI, Yurchenko OV, Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2006;231:87-93
   PubMed Web of Science ®Google Scholar
• Pakneshan P, Szyf M, Rabbani SA. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 2005;5:471-88
   PubMed Web of Science ®Google Scholar
• Pulukuri SM, Rao JS. Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 2007;67:6637-46
   PubMed Web of Science ®Google Scholar
• Jing Y, Tong C, Zhang J, Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res 2009;69:1459-68
   PubMed Web of Science ®Google Scholar
• Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001;276:17976-84
   PubMed Web of Science ®Google Scholar
• Brooks TD, Slomp J, Quax PH, Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clin Exp Metastasis 2000;18:445-53
   PubMed Web of Science ®Google Scholar
• Leik CE, Su EJ, Nambi P, Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006;4:2710-5
   PubMed Web of Science ®Google Scholar
• Mutoh M, Niho N, Komiya M, Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008;29:824-9
   PubMed Web of Science ®Google Scholar